Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-01

Study Completion Date

2019-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

22 asthmatics, in which mepolizumab was to be started, gave permission for inclusion and were followed up prospectively. Clinical and lung functional data, sputum analyses and cytokine measurements were analyzed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Anti-IL-5/IL5R Inhibitors

NCT06239441

Severe Asthma

COMPLETED

Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

NCT06348173

Asthma

COMPLETED

Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)

NCT04612556

Asthma; Eosinophilic Severe Asthma Late-Onset Asthma

ACTIVE_NOT_RECRUITING

Poor Response to Monoclonal Therapy in Asthma

NCT04114396

Asthma

UNKNOWN

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

NCT00483041

Asthma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asthmatics

Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment

Group Type EXPERIMENTAL

Mepolizumab Injection [Nucala]

Intervention Type DRUG

Patients receive monthly injection with 100 mg mepolizumab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mepolizumab Injection [Nucala]

Patients receive monthly injection with 100 mg mepolizumab

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anti-IL5 treatment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* FEV1 \< 80% in the last 12 months
* use of high dose inhaled corticosteroids (ICS) in combination with other additional medication or continuous use of oral corticosteroids (OCS)
* at least 2 exacerbations in the last 12 months
* at least 300 blood eosinophils/µl once in the last 12 months and at the time of inclusion
* Anti-IL5 treatment prescribed by the physician